The 2006 consensus guidelines for the management of women with abnormal cervical screening tests: Challenges remain

Cancer Cytopathology

Volumn 118, Issue 5, 2010, Pages 233-237

  Colgan, Terence J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Abnormal cytology; Compliance; Guidelines; Human papillomavirus (HPV) testing; Papanicolaou test

Indexed keywords

ARTICLE; COLPOSCOPY; CONSENSUS DEVELOPMENT; FEMALE; HUMAN; INSTRUMENTATION; MASS SCREENING; METHODOLOGY; PATHOLOGY; PRACTICE GUIDELINE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; UTERINE CERVIX; UTERINE CERVIX TUMOR;

CERVIX UTERI; COLPOSCOPY; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; FEMALE; HUMANS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 79952114369     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20097     Document Type: Review

References (26)

1. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120-2129.
2. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007;11:201-222.
3. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis. 2007;11:223-239.
4. Benard VB, Lawson HW, Eheman CR, Anderson C, Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol. 2005;105:1323-1328.
5. Holland-Barkis P, Forjuoh SN, Couchman GR, Capen C, Rascoe TG, Reis MD. Primary care physicians' awareness and adherence to cervical cancer screening guidelines in Texas. Prev Med. 2006;42:140-145.
6. Moriarty AT, Cibas ES. Endometrial cells: the how and when of reporting. In: Solomon D, Nayar R, eds. The Bethesda System for Reporting Cervical Cytology. 2nd ed. New York: Springer; 2004:57-65.
7. Moroney JW, Zahn CM, Heaton RB, Crothers B, Kendall BS, Elkas JC. Normal endometrial cells in liquid-based cervical cytology specimens in women aged 40 or older. Gynecol Oncol. 2007;105:672-676.
8. Greenspan DL, Cardillo M, Davey DD, Heller DS, Moriarty AT. Endometrial cells in cervical cytology: review of cytological features and clinical assessment. J Low Genit Tract Dis. 2006;10:111-122.
9. Barreth D, Faught W, Schepansky A, Johnson G. The relationship between atypical glandular cells of undetermined significance on Pap smear and a clinically significant histologic diagnosis. J Obstet Gynaecol Can. 2004;26:867-870.
10. Sharpless K, Robinson C, Schnatz P. Adherence to practice guidelines for women with atypical glandular cells on cervical cytology: a follow-up analysis. Paper presented at: The American Society for Colposcopy and Cervical Pathology (ASCCP) Biennial Meeting; March 24-27, 2010; Las Vegas, Nevada.
11. Moriarty AT, Schwartz MR, Eversole G, et al. Human papillomavirus testing and reporting rates: practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Gynecologic Cytology in 2006. Arch Pathol Lab Med. 2008;132:1290-1294.
12. Lee JW, Berkowitz Z, Saraiya M. Low-risk human papillomavirus testing among U.S. Pap test providers, 2006. Paper presented at: The American Society for Colposcopy and Cervical Pathology (ASCCP) Biennial Meeting; March 24-27, 2010; Las Vegas, Nevada.
13. Butler SL, Wilkinson EJ. Profiles of oncogenic HPV ordering: ASCCP/ACS guideline vs non-guideline compliance. Paper presented at: The American Society for Colposcopy and Cervical Pathology (ASCCP) Biennial Meeting; March 24-27, 2010; Las Vegas, Nevada.
14. Davion S, Lucas E, Kemp A, Nayar R. HPV DNA testing: is it used appropriately? Mod Pathol. 2010;23:232A-270A.
15. Jeronimo J, Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol. 2006;195:349-353.
16. Solomon D, Papillo J, Davis Davey D; Cytopathology Education and Technology Consortium. Statement on HPV DNA test utilization. J Low Genit Tract Dis. 2009; 13:135-136.
17. American Society for Colposcopy and Cervical Pathology. Descriptions of new FDA-approved HPV DNA tests. Available at: http://www.asccp.org/pdfs/ consensus/clinical-update-20090408.pdf. Accessed March 31, 2010.
18. Sherman ME, Wang SS, Tarone R, Rich L, Schiffman M. Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the atypical squamous cells of undetermined significance low-grade squamous intraepithelial lesion triage study: implications for subject safety and lead-time bias. Cancer Epidemiol Biomarkers Prev. 2003;12:372-379.
19. Sellors JW, Qiao Y, Bao Y, et al. False-negative colposcopy: quantifying the problem. Paper presented at: 22nd International HPV Conference and Clinical Workshop; April 30-May 6, 2005; Vancouver, British Columbia, Canada.
20. Pretorius RG, Zhang WH, Belinson JL, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol. 2004;191:430-434.
21. Pretorius R, Belinson J, Burchette R, Hu S, Qiao Y. Regardless of skill, performing more biopsies improves colposcopic accuracy. Paper presented at: The American Society for Colposcopy and Cervical Pathology (ASCCP) Biennial Meeting; March 24-27, 2010; Las Vegas, Nevada.
22. Nam K, Chung S, Kim J, Jeon S, Cho Y, Bae D. Are random biopsies in addition to colposcopy directed biopsy necessary in the diagnosis of cervical intraepithelial neoplasia (CIN) II or worse? Paper presented at: The American Society for Colposcopy and Cervical Pathology (ASCCP) Biennial Meeting; March 24-27, 2010, Las Vegas, Nevada.
23. Wentzensen N, Zuna RE, Sherman ME, et al. Accuracy of cervical specimens obtained for biomarker studies in women with CIN3. Gynecol Oncol. 2009;115:493-496.
24. Gage JC, Hanson VW, Abbey K, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol. 2006; 108:264-272.
25. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197:356.e1-6.
26. Austin R, Onisko A, Druzdzel M. The Pittsburgh Cervical Cancer Screening Model. A risk assessment tool. Arch Pathol Lab Med. 2010;134:744-750.